Aquestive Therapeutics (AQST) News Today $4.44 -0.13 (-2.84%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?November 16 at 9:20 AM | msn.comChartwell Investment Partners LLC Acquires Shares of 107,550 Aquestive Therapeutics, Inc. (NASDAQ:AQST)Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 107,550 shares of thNovember 14 at 4:02 AM | marketbeat.comPositive Developments and Strategic Partnerships Justify Buy Rating for Aquestive TherapeuticsNovember 11, 2024 | markets.businessinsider.comAquestive Therapeutics' (AQST) Buy Rating Reiterated at HC WainwrightNovember 10, 2024 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for AQSTNovember 10, 2024 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for AQST FY2024 Earnings?November 9, 2024 | americanbankingnews.comHC Wainwright Issues Pessimistic Estimate for AQST EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Aquestive Therapeutics in a report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the comNovember 8, 2024 | marketbeat.comLeerink Partnrs Has Strong Estimate for AQST FY2024 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now anticipates thNovember 8, 2024 | marketbeat.comAquestive Therapeutics Announces Board and Committee ChangesNovember 7, 2024 | markets.businessinsider.comAquestive Therapeutics: Strong Buy Rating Driven by Robust Revenue Performance and Strategic Positioning in Allergy TreatmentNovember 7, 2024 | markets.businessinsider.comAquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 6, 2024 | finance.yahoo.comPromising Future and Strategic Advancements: Buy Recommendation for Aquestive TherapeuticsNovember 6, 2024 | markets.businessinsider.comLake Street Sticks to Their Buy Rating for Aquestive Therapeutics (AQST)November 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Strong Product Pipeline and Financial StabilityNovember 6, 2024 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...November 6, 2024 | finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday.November 6, 2024 | marketbeat.comAquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comAquestive: Rare Opportunity With Dual Platform StrategyNovember 5, 2024 | seekingalpha.comAquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPSAquestive Therapeutics (NASDAQ:AQST - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analysts' expectations of $12.69 million. During the same quarter in the prior year, the company earned ($0.03) EPS.November 5, 2024 | marketbeat.comAquestive Therapeutics Optimistic Financial and Strategic OutlookNovember 5, 2024 | markets.businessinsider.comAquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To ExpectNovember 4, 2024 | finance.yahoo.comAquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | globenewswire.comAquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 1, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of "Buy" by AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buNovember 1, 2024 | marketbeat.comAquestive Therapeutics (AQST) Set to Announce Earnings on MondayAquestive Therapeutics (NASDAQ:AQST) will be releasing earnings after the market closes on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637658)October 28, 2024 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)October 25, 2024 | markets.businessinsider.comAquestive Therapeutics (NASDAQ:AQST) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday.October 25, 2024 | marketbeat.comAquestive announces primary, secondary endpoints met in OAS challenge studyOctober 24, 2024 | markets.businessinsider.comAquestive Therapeutics’ Breakthrough in Allergy Treatment StudyOctober 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)October 8, 2024 | markets.businessinsider.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned an average rating of "Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy ratingOctober 7, 2024 | marketbeat.comRenaissance Technologies LLC Has $1.29 Million Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Renaissance Technologies LLC reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 63.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 496,200 shares of the company's stock after selling 879,600 shares during the peOctober 6, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)October 1, 2024 | markets.businessinsider.comAquestive Therapeutics: Strong Buy Rating on Innovative Pipeline and Market PotentialOctober 1, 2024 | markets.businessinsider.comBuy Rating Affirmed on Aquestive Therapeutics Amidst Promising AQST-108 Developments and Market PotentialOctober 1, 2024 | markets.businessinsider.comAquestive Therapeutics' (AQST) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Monday.September 30, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) PT Raised to $10.00 at HC WainwrightHC Wainwright upped their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday.September 30, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Raised by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP boosted its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 30.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,140,000 shares of the company's stocSeptember 28, 2024 | marketbeat.comAquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor DaySeptember 27, 2024 | globenewswire.comBank of New York Mellon Corp Invests $594,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Bank of New York Mellon Corp acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 228,351 shares of the company's stocSeptember 24, 2024 | marketbeat.comAquestive Therapeutics: A Buy Rating on Underappreciated Market Potential and Innovative PipelineSeptember 13, 2024 | markets.businessinsider.comAquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27thSeptember 9, 2024 | globenewswire.comAquestive Therapeutics to Participate in Two Upcoming Investor ConferencesAugust 22, 2024 | globenewswire.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coAugust 18, 2024 | marketbeat.comAQST Sep 2024 0.500 call (AQST240920C00000500)August 16, 2024 | finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday.August 14, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 71.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,242,571 shares of the company's stock after buying an additional 1,353,518 shares during the quarteAugust 14, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)August 12, 2024 | markets.businessinsider.comAquestive Therapeutics (NASDAQ:AQST) Rating Reiterated by JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Monday.August 12, 2024 | marketbeat.com Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.410.56▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼93▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XERS News OPTN News CMRX News FBIO News WVE News NAMS News SNDX News IMCR News OCUL News EVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQST Stock Alerts